Sutro Biopharma GAAP EPS of -$2.94, revenue of $14.52M
Source: SeekingAlpha
2026-05-14 16:38:51 ET
More on Sutro Biopharma
- Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell
- Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - Slideshow
- Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
- Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M
- Seeking Alpha’s Quant Rating on Sutro Biopharma
Read the full article on Seeking Alpha
For further details see:
Sutro Biopharma GAAP EPS of -$2.94, revenue of $14.52M
Sutro Biopharma Inc.
NASDAQ: STRO
STRO Trading
0.52% G/L:
$39.78 Last:
49,363 Volume:
$43.85 Open:
STRO Latest News
May 14, 2026 04:05:00 pm
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsApril 19, 2026 07:45:00 pm
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026March 23, 2026 04:05:00 pm
Sutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsSTRO Stock Data
$132,896,188
8,207,042
0.54%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
